Comparative Efficacy of Peptides vs. AAS
Anabolic steroids have far stronger human evidence for building muscle than the peptides lifters use, which rest mostly on animal data. This page compares their risks and their legal status as of October 2026.
How Peptides and AAS Differ
Peptides and anabolic-androgenic steroids (AAS) get compared constantly, but they act at different points. AAS bind the androgen receptor directly. The peptides lifters usually mean either raise the body's own growth hormone (secretagogues such as ipamorelin) or are recovery compounds such as BPC-157 and TB-500, studied mainly in rodents.
Mechanisms of Action
Peptides
Growth hormone secretagogues stimulate growth hormone release. No trial has shown that they build muscle in healthy lifters. For growth hormone itself, a 2008 systematic review of trials in fit young adults found about 2.1 kg more lean mass but no clear strength gain.
AAS
AAS mimic the effects of testosterone, leading to increased muscle mass and strength. Androgen receptors sit in many tissues besides muscle, so the side effects reach well beyond it.
Comparative Benefits
In a 1996 New England Journal of Medicine trial, 43 healthy men received 600 mg of testosterone enanthate or placebo weekly for 10 weeks. Men on testosterone who also trained gained 6.1 kg of fat-free mass.
The peptide evidence is much thinner. As of October 2026, we rate ipamorelin's evidence as moderate and BPC-157's as emerging (a 2025 review found 35 of 36 studies were preclinical). TB-500 is preliminary; FDA says it has no human exposure data.
| Aspect | Peptides | AAS |
|---|---|---|
| Muscle growth | Not tested in people | 6.1 kg fat-free mass in 10 weeks |
| Recovery | Rodent data only | Not measured in trials |
| Side effect profile | Little human data | Well documented, often serious |
| Natural hormone impact | Growth hormone axis | Highly suppressive |
Risks Comparison
Peptide Risks
- Injection site reactions
- Uncertain purity of research-market vials
- Water retention, seen with growth hormone in trials
- Little long-term safety data
AAS Risks
A 2014 Endocrine Society statement linked performance-enhancing drugs, including AAS, to higher death risk and to cardiovascular and psychiatric disorders, among others.
- Liver damage (oral steroids)
- Cardiovascular disease
- Hormonal shutdown
- Mental health effects
- Androgenic side effects
Legal and Regulatory Considerations
As of October 2026, AAS are Schedule III controlled substances under US federal law. Peptides aren't controlled, but that doesn't make them a lightly regulated grey area: in 2026 warning letters, FDA told online sellers that "research use only" labels didn't protect them when their websites showed the products were meant for people. In sport, WADA's 2026 list bans AAS under S1.1, BPC-157 under S0 and TB-500 under S2.3. Growth hormone secretagogues fall under S2.2.4 and myostatin inhibitors under S4.3. See our peptide legal status hub for details.
Where Myostatin Drugs Fit
As of October 2026, apitegromab is the first FDA-approved myostatin-targeted drug, cleared in September 2026 for spinal muscular atrophy. In obesity trials, bimagrumab (BELIEVE) and trevogrumab (COURAGE) reduced lean-mass loss on semaglutide, but neither was tested for building muscle. Our comparison of myostatin inhibitors and anabolics covers those trials.
Comparison table
| Dimension | Peptides | Anabolic steroids | SARMs |
|---|---|---|---|
| Mechanism | Growth hormone release or repair pathways | Androgen receptor | Androgen receptor |
| Primary use case | Recovery or growth hormone goals | Muscle gain | Muscle gain |
| Typical dose range | Compound-specific | Compound-specific | Unknown |
| Half-life | Varies by peptide | Varies by compound | Unknown |
| Common side effects | Injection reactions | Hormone or tissue risk | Not covered here |
| WADA status (2026 list) | S0, S2.2.4 or S2.3 | Prohibited (S1.1) | Prohibited (S1.2) |
| Evidence strength | Preliminary to moderate | Strong | Not covered here |
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men (New England Journal of Medicine, 1996)
- Systematic review: the effects of growth hormone on athletic performance (Annals of Internal Medicine, 2008)
- Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement (Endocrine Reviews, 2014)
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (HSS Journal, 2025)
- Certain bulk drug substances for use in compounding that may present significant safety risks, including TB-500 and ipamorelin (FDA, updated April 2026)
- Warning letter to Gram Peptides on research-use-only labeling (FDA, March 31, 2026)
- Warning letter to Peak Performance Peptides (FDA, August 24, 2026)
- 21 CFR 1308.13, Schedule III, including anabolic steroids (eCFR, accessed October 2026)
- World Anti-Doping Code 2026 Prohibited List (WADA, 2025)
- FDA approves first therapy to target muscle loss in spinal muscular atrophy (FDA, September 2026)
- Bimagrumab and semaglutide, alone or in combination, for obesity: BELIEVE randomized Phase 2 trial (Nature Medicine, 2026)
- Phase 2 COURAGE data: trevogrumab preserves lean mass during semaglutide weight loss (MedPath, October 2026)